PBAC approves long-acting injectable PrEP for HIV
Cabotegravir was approved by the TGA last year.
Patients with contraindications to daily oral HIV pre-exposure prophylaxis could soon access a PBS-subsidised long-acting injectable.
Following its September meeting, the PBAC has recommended a streamlined authority listing for long-acting cabotegravir (Apretude) as a HIV pre-exposure prophylaxis (PrEP) alternative.
The antiviral, which was approved by the TGA in 2022, is an integrase strand transfer inhibitor that disrupts the HIV replication cycle.
Patients must have a documented negative HIV test before starting treatment and weigh at least 35kg, according to the product information.
